	US 12,291,707 B2
	Modified immune cells having enhanced function and methods for screening the same
Yangbing Zhao, Lumberton, NJ (US); and Jiangtao Ren, Philadelphia, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Jan. 29, 2024, as Appl. No. 18/424,952.
Application 18/424,952 is a division of application No. 17/743,183, filed on May 12, 2022, granted, now 11,920,130.
Application 17/743,183 is a division of application No. 16/365,326, filed on Mar. 26, 2019, granted, now 11,447,769, issued on Aug. 31, 2022.
Claims priority of provisional application 62/648,722, filed on Mar. 27, 2018.
Prior Publication US 2024/0167024 A1, May 23, 2024
Int. Cl. C12N 15/11 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 15/10 (2006.01)

CPC C12N 15/11 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4269 (2025.01); A61K 40/4274 (2025.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 15/1082 (2013.01); A61K 2239/54 (2023.05); A61K 2239/57 (2023.05); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

5 Claims

1. A modified immune cell or precursor cell thereof, comprising:

an insertion and/or deletion in one or more gene loci encoding for a protein selected from the group consisting of AZI2, C1orf141, CCDC33, CCL7, CEACAM19, MFSD5, PAGR1, SIX2, and USP27X, wherein the insertion and/or deletion is capable of downregulating gene expression of the one or more endogenous genes; and

an exogenous T cell receptor (TCR) and/or chimeric antigen receptor (CAR) comprising affinity for an antigen on a target cell.